Filtered By:
Condition: Chronic Obstructive Pulmonary
Drug: Xolair

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

Plasma Immunoglobulin E and Risk of Exacerbation and Mortality in COPD: A Contemporary Population-Based Cohort
CONCLUSION: High plasma IgE was associated with an increased risk of severe exacerbation and all-cause mortality in individuals with COPD in the general population independent from blood eosinophils.PMID:35835293 | DOI:10.1016/j.anai.2022.06.028
Source: Annals of Allergy, Asthma and Immunology - July 14, 2022 Category: Allergy & Immunology Authors: Yunus Çolak Truls S Ingebrigtsen B ørge G Nordestgaard Jacob L Marott Peter Lange J ørgen Vestbo Shoaib Afzal Source Type: research

Strategies for choosing a biologic for your patient with allergy or asthma
CONCLUSION: The numerous biologic options have made the selection of the best biologic for each patient a potential conundrum for clinicians. Adequate point of care biomarkers to facilitate personalized medical therapy are generally lacking. Furthermore, although clinically effective and generally safe, none of the biologics discussed in this review have induced long-standing disease remission. Nevertheless, these agents have given us the opportunity to treat the most severe patients and to better understand the biology of respiratory and allergic diseases. As knowledgeable physicians, we should embrace and be educated on ...
Source: Annals of Allergy, Asthma and Immunology - October 13, 2021 Category: Allergy & Immunology Authors: Tara Saco Israel C Ugalde Juan Carlos Cardet Thomas B Casale Source Type: research

Prevention of lung function decline by real-life long-term omalizumab therapy in children with severe asthma
Omalizumab (OMA) to treat severe allergic asthma is effective in preventing asthma exacerbation and improving asthma control. Efficacy for lung function, however, is controversial. Low lung function in childhood tracks to the later life and is a risk of COPD. Prevention of lung function decline may be vital to avoid the long-term sequala.
Source: Journal of Allergy and Clinical Immunology - January 31, 2020 Category: Allergy & Immunology Authors: Mizuho Nagao, Takao Fujisawa Source Type: research

Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
This study assessed omalizumab outcomes in real-world patients with allergic asthma stratified by pretreatment biomarker levels. METHODS: Patients with allergic asthma aged ≥12 years initiated on omalizumab with ≥12 months of data after index were identified in the Allergy Partners electronic medical records (2007-2018). Patients with ≥1 diagnosis of chronic obstructive pulmonary disease in combination with ≥10 pack-years of smoking, cystic fibrosis, Alpha-1 antitrypsin deficiency, bronchiectasis, interstitial lung disease, and sarcoidosis in the 12 months before or after index were excluded. Patients were str...
Source: Clinical Therapeutics - September 24, 2019 Category: Drugs & Pharmacology Authors: Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, Ho H, Lefebvre P, Stone B Tags: Clin Ther Source Type: research

Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO
Asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO), defined as the coexistence of clinical features of asthma and COPD, is common.1,2 Although ACO is heterogeneous, common subphenotypes of ACO include those with asthma who are older than 40  years with a history of smoking and/or those who have persistent, progressive, and partially reversible airflow limitation.2
Source: Journal of Allergy and Clinical Immunology - December 18, 2018 Category: Allergy & Immunology Authors: Nicola A. Hanania, Bradley E. Chipps, Noelle M. Griffin, Bongin Yoo, Ahmar Iqbal, Thomas B. Casale Tags: Letter to the Editor Source Type: research

Omalizumab effectiveness in Asthma COPD overlap: post hoc analysis of PROSPERO study
Patients with asthma and COPD overlap (ACO) are poorly represented in asthma clinical trials. This post hoc analysis of a large, real-world study demonstrates that omalizumab may be beneficial in patients with ACO.
Source: Journal of Allergy and Clinical Immunology - December 18, 2018 Category: Allergy & Immunology Authors: Nicola A. Hanania, Bradley E. Chipps, Noelle M. Griffin, Bongin Yoo, Ahmar Iqbal, Thomas B. Casale Source Type: research

Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence
AbstractPurpose of ReviewExamine the definition of the asthma-COPD overlap syndrome (ACOS) and current treatment strategies.Recent FindingsPatients with the ACOS have a lower quality of life and suffer from more complications than those affected by either disease alone. Diagnosis of ACOS is difficult because of the clinical similarities between the two diseases and the various phenotypes that comprise the syndrome. Defining treatment strategies for ACOS has been challenging because many clinical trials for asthma therapy have purposefully excluded patients with features of COPD, and COPD clinical trials have not included p...
Source: Current Allergy and Asthma Reports - March 9, 2017 Category: Allergy & Immunology Source Type: research

Omalizumab Offers Improvements in Patients with Asthma-COPD (CME/CE)
(MedPage Today) -- Better asthma control and QoL scores, but no lung function improvement
Source: MedPage Today Allergy - November 8, 2016 Category: Allergy & Immunology Source Type: news

A case diagnoed ACOS with omelizumab treatment
ACOS Asthma- COPD overlap syndrome causes major problems in differential diagnosis of especially in smoking and older patients. ACOS carrying some characteristics of both asthma and COPD, is clinically markedly worst then both. Patients with ACOS, has a rapid worsening of pulmonary function tests, high ratios of exacerbations, multi symptoms, worst quality of life and a higher cost of administration. Estimated ratio of ACOS among asthmatic and COPD is as high as 15-55 %. In the history of 57 years old dyspneic patient there are childhood onset asthma, allergic rhinitis lasting about 20 years, diabetes mellitus and hyperten...
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Salik, B., Komurcuoglu, B., Yalniz, E. Tags: 1.11 Clinical Problems - Asthma Source Type: research

Allergic bronchopulmonary aspergillosis complicating COPD is associated with a higher exacerbation rate and a distinct pattern on chest CT scan compared to COPD
Recent data support that patients with COPD can experienced associated asthma in an overlap syndrome. This raise hypothesis of specific complications in these patients as allergic broncho-pulmonary aspergillosis (ABPA), usually seen in asthma patients, exhibiting potential specific features when associated to COPD. We compiled 16 cases of ABPA (Patterson criteria) diagnosed in COPD patients (GOLD criteria,Tabaco > 10 PY) in a monocentrique retrospective study, then compared to 16 COPD matched patients on age and FEV1, with similar overall follow up (7.8 years). ABPA-COPD group age was 61.1 years, FEV1 was 36% (1127mL), ...
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Maignant, A., Mellot, F., Haudebourg, L., Neveu, H., Rivaud, E., Catherinot, E., Bron, C., Salvator, H., Chabrol, A., Anitei, O., Trebbia, G., Devaquet, J., Cerf, C., Couderc, L.-J., Tcherakian, C. Tags: 5.3 Allergy and Immunology Source Type: research

XXIV World Allergy Congress 2015
Table of Contents A1 Pirfenidone inhibits TGF-b1-induced extracellular matrix production in nasal polyp-derived fibroblasts Jae-Min Shin, Heung-Man Lee, Il-Ho Park A2 The efficacy of a 2-week course of oral steroid in the treatment of chronic spontaneous urticaria refractory to antihistamines Hyun-Sun Yoon, Gyeong Yul Park A3 The altered distribution of follicular t helper cells may predict a more pronounced clinical course of primary sjögren’s syndrome Margit Zeher A4 Betamethasone suppresses Th2 cell development induced by langerhans cell like dendr...
Source: World Allergy Organization Journal - April 18, 2016 Category: Allergy & Immunology Source Type: research

The dendritic cell high‐affinity IgE receptor is overexpressed in both asthma and severe COPD
Conclusions and Clinical RelevanceSevere COPD and allergic asthma are characterized by a similar overexpression of the high‐affinity IgE receptor on plasmacytoid DCs. In view of the effect of anti‐IgE on exacerbations in asthma, trials investigating the effect of anti‐IgE on exacerbations in severe COPD appear to be warranted.
Source: Clinical and Experimental Allergy - March 28, 2016 Category: Allergy & Immunology Authors: P. Stoll, A. Bähker, M. Ulrich, K. Bratke, K. Garbe, J. Christian Virchow, M. Lommatzsch Tags: Original Article Source Type: research